Metropolis Healthcare Limited — Important, 05-04-2025: Updates

The healthcare industry faced challenges in Q4, leading to weaker performance across several sectors. Metropolis Healthcare experienced a slowdown in the acute testing segment due to adverse weather, affecting outpatient visits and patient volumes. Additionally, reduced elective procedures in major hospitals impacted the specialty testing business. Nonetheless, the company achieved approximately 10% year-over-year revenue growth, fueled by increased patient and test volumes, along with a favorable product mix. Notably, B2C revenues grew around 14% year-over-year, driven by an enhanced consumer experience and expanded service network.

Operational EBITDA showed slight growth, although impacted by higher material costs and one-time expenses related to the acquisition costs for Core Diagnostics & Scientific Pathology. The company remains debt-free, with cash reserves of about INR 112 crores, following payments of INR 130 crores for acquisitions. The quarterly update reflects consolidated results, incorporating Core Diagnostics’ financials for a brief operational period, and indicates that EBITDA for Core Diagnostics is at break-even.